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Germline mutations in the LKB1/STK11 tumour suppressor gene cause Peutz–Jeghers syndrome (PJS), a rare dominant disorder. In
addition to typical hamartomatous gastrointestinal polyps and pigmented perioral lesions, PJS is associated with an increased risk of
tumours at multiple sites. Follow-up information on carriers is limited and genetic heterogeneity makes counselling and management
in PJS difficult. Here we report the analysis of the LKB1/STK11 locus in a series of 33 PJS families, and estimation of cancer risks in
carriers and noncarriers. Germline mutations of LKB1/STK11 were identified in 52% of cases. This observation reinforces the
hypothesis of a second PJS locus. In carriers of LKB1/STK11 mutations, the risk of cancer was markedly elevated. The risk of
developing any cancer in carriers by age 65 years was 47% (95% CI: 27–73%) with elevated risks of both gastrointestinal and breast
cancer. PJS with germline mutations in LKB1/STK11 are at a very high relative and absolute risk of multiple gastrointestinal and
nongastrointestinal cancers. To obtain precise estimates of risk associated with PJS requires further studies of genotype–phenotype
especially with respect to LKB1/STK11 negative cases, as this group is likely to be heterogeneous.
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Peutz–Jeghers syndrome (PJS; MIM 175200) is an autosomal
dominant disorder characterised by a specific form of hamarto-
matous polyposis of the gastrointestinal tract, and by melanin
pigmentation of the lips, perioral region and buccal mucosa,
fingers and toes, and other sites (Tomlinson and Houlston, 1997).
Approximately three-quarters of PJS are familial, the remainder
resulting from new mutations or low-penetrance variants. PJS
typically presents in early childhood with pigmentation or with
complications of small bowel polyps–intussusception, obstruction
or bleeding.
Although PJS polyps are seen most commonly in the small
bowel, they can occur throughout the gastrointestinal tract
(Tomlinson and Houlston, 1997) and at other extra-intestinal sites
such as the kidney, ureter, gall bladder, bronchus and nasal
passage (Westerman et al, 1999; Sommerhaug et al, 1970; Wada
et al, 1987). The polyps seen in PJS have a muscular core and are
generally classified as being hamartomas. Nevertheless, adenoma-
tous change may occur in polyps and they may become malignant,
and an increased risk of jejunal and other small bowel tumours is
recognised (Gruber et al, 1998).
In addition to an elevated risk of gastrointestinal malignancies,
an increased risk of cancers at other sites is recognized; in
particular, breast, pancreas, ovary, uterus, cervix, lung and
testicular cancers have been reported (Giardello et al, 1987, 2000;
Spigelman et al, 1989). Testicular sex cord and Sertoli-cell tumours
may occur in prepubertal boys affected with PJS leading to sexual
precocity and gynaecomastia (Wilson et al, 1986; Coen et al, 1991;
Young et al, 1995). The production of oestrogen in ovarian
tumours in girls with PJS has also been reported causing isosexual
precocity (Sohl et al, 1983).
Germline mutations in the serine/threonine kinase gene (LKB1/
STK11) on chromosome 19p13.3 have been shown to cause PJS
(Hemminki et al, 1997; Hemminki et al, 1998; Jenne et al, 1998).
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nine exons, and functions as a tumour suppressor.
Previous studies have shown that between 30 and 82% of
patients have no detectable germline mutations in LKB1/STK11
(Mehenni et al, 1998; Nakagawa et al, 1998; Jiang et al, 1999; Wang
et al., 1999; Westerman et al, 1999b; Ylikorkala et al, 1999;
Boardman et al, 2000; Yoon et al, 2000; Olschwang et al, 2001).
Families with PJS unlinked to 19p13.3 have also been reported,
suggesting that the disease is heterogeneous (Jiang et al, 1999;
Westerman et al, 1999b; Yoon et al, 2000). Furthermore, a second
PJS locus on chromosome 19q13.4 has been proposed on the basis
of linkage in one family (Mehenni et al, 1998).
The clinical features of PJS are variable especially with respect to
cancer risks. It is likely that inter- and intrafamilial differences in
disease expression reflect in part the influence of different
germline mutations.
To further our knowledge about the relation between genotype
and cancer risk in PJS, we have related disease expression to LKB1/
STK11 status in 33 families.
PATIENTS AND METHODS
Patients
Thirty-three index patients with PJS were ascertained through
colorectal surgeons, gastroenterologists and geneticists within the
UK. Clinical information was collected on all patients using a
standard proforma and through access to patients’ medical
records. PJS was defined according to published diagnostic criteria
(Giardello et al, 1987)–histopathologically verified hamartoma-
tous polyps with at least two of the following: small bowel
polyposis, mucocutaneous melanotic pigmentation and family
history of the disease. Patients were asked to provide details of any
cancer in first- and second-degree relatives. There was no selection
of cases for a family history of cancer. Clinical information and
samples were obtained with informed consent and Local Ethical
Review Board approval in accordance with the tenets of the
Declaration of Helsinki.
Mutational analysis of LKB1/STK11
Genomic DNA from PJS patients was isolated from EDTA venous
blood samples using a standard sucrose lysis protocol. The search
for germline mutations in LKB1/STK11 was performed using
conformational sensitive gel electrophoresis (CSGE) as described
by Ganguly et al (1993). Published oligonucleotide primer
sequences were used to amplify each of the nine exons of LKB1/
STK11 (Bignell et al, 1998). Any fragments showing migration
shifts were reamplified and sequenced directly using the ABI Prism
dRhodamine Terminator Cycle Sequencing Ready Reaction Kit
and an ABI377 Genetic Analyser. For all samples with possible
mutations, sequencing was replicated in forward and reverse
orientation using an additional affected family member (or using
the original patient if no other affected individual had been
sampled) in order to confirm the presence of the mutation. A
search for large-scale deletions in LKB1/STK11 was made by long-
range PCR. Amplification of exons 3–8 of LKB1/STK11 was
undertaken using the Expand Long Template PCR System (Roche
Diagnostics, UK).
Nucleotide changes identified were coded according to the
published sequence of LKB1/STK11 (Genbank accession numbers:
exon 1, AF032984; exons 2–8, AF032985; exon 9, AF032986) and
referenced to the Human Gene Mutation Database (http://
archive.uwcm.ac.uk/uwcm/mg).
A search of the literature was made using the electronic database
MEDLINE (National Library of Medicine, USA) for additional
mutations reported to be associated with PJS which were not
referenced in the Human Gene Mutation Database. LKB1/STK11
protein sequences of Homo sapiens (GenBank accession number
NP 000446), Mus musculus (NP 035622) and XEEK1 (Q91604) were
obtained from the NCBI protein database. They were aligned using
Clustal W (1.82) multiple sequence alignment program (http://
www.ebi.ac.uk/clustalw/).
Statistical analyses
Statistical analyses were performed using the statistical software
program STATA Version 6 (Stata Corporation, TX, USA. http://
www.stata.com). The 95% confidence interval (CI) of the estimate
of the frequency of LKB1/STK11 mutations in PJS was estimated
from the binomial distribution. The association between catego-
rical variables was made using either Fisher or w
2 tests, and
differences in the distribution of continuous variables were
evaluated using the Mann–Whitney U-test. Estimation of cancer
risks was made excluding cases that had developed neoplasms
either before or at the time of presentation of PJS. Estimates of
cancer risks were obtained from survival analyses and standar-
dised mortality ratios (SMRs). SMRs for cancers were determined
using life-table methods. Cases were considered at risk from age 5
until the date of diagnosis of cancer or date of ascertainment,
censoring at age 65. Expected numbers of cancers were computed
using age-, sex- and calendar period-specific mortality rates for
England and Wales referenced to the International Classification of
Diseases, ninth revision (ICD-9)–all cancers 140–208, cancers of
the digestive organs and peritoneum 150–159 and breast
carcinoma 174. Two-sided 95% CIs for relative risk estimates are
based on the Poisson distribution. A P-value of 0.05 was
considered statistically significant.
RESULTS
Table 1 details the clinical characteristics and family histories of
the 33 index patients analysed. Of these cases, 13 were familial and
20 sporadic. Germline LKB1/STK11 mutations were identified in 17
of the 33 (52%; 95% CI: 33–69%) patients (Table 1), in exons 1–8.
We cannot exclude the possibility that some mutations may
have gone undetected; however, under test conditions, we have
found that CSGE can detect all small insertions and deletions and
B90% of single-base substitutions. In addition, we have examined
for the possibility that some cases might harbour large-scale
deletions in LKB1/STK11. It is therefore unlikely that we have
failed to detect coding mutations, and, allowing for 90% sensitivity,
the results suggest that the mutations in LKB1/STK11 account for
at best 75% of PJS cases (the upper 95% confidence limit). Two
patients carried the same mutation in exon 6 (PJ42 and PJ51) and
two carried the same mutation at the 50 splice site of exon 8 (PJ33
and PJ61). These four patients were ascertained from different
centres and were not known to have any common ancestry.
Nevertheless, as all are from the UK, it is probable that these
mutations have a common origin, although identical LKB1/STK11
mutations without evidence of common ancestry have been
reported (Hemminki et al, 1998; Resta et al, 1998; Wang et al,
1999; Westerman et al, 1999b; Ylikorkala et al, 1999). None of the
patients studied were shown to harbour large-scale deletions of
LKB1/STK11.
No significant bias towards mutations in exons 1 or 6 was
observed, but no exon 9 mutations were identified. Seven of the 15
different mutations identified have not been reported previously–
336delG (Q112fsX17), 369delG (Q123fsX6), 427delG (V143fsX144),
718_719insA (S240fsX26), G725A (G242E), 815_816insA (Y272X),
IVS8-2A4G (altered splicing). In all, 11 of the mutations are
predicted to lead to a truncated protein (four nonsense mutations,
four frameshift deletions, one frameshift insertion and two splice
site mutations). The other mutations identified were missense
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smutations, three of which have previously been reported to be
pathogenic (Resta et al, 1998; Westerman et al, 1999b; Ylikorkala
et al, 1999). All are nonconservative amino-acid changes that are
highly conserved among human, mouse and Xenopus homologues
of LKB1/STK11 and reside within the protein kinase core of LKB1/
STK11 (Collins et al, 2000).
Table 2 shows the positions of the mutations observed in our
study and in previously published reports (Hemminki et al, 1998;
Gruber et al, 1989; Jenne et al, 1998; Mehenni et al, 1998;
Nakagawa et al, 1998; Resta et al, 1998; Jiang et al, 1999; Kruse et al,
1999; Wang et al, 1999; Westerman et al, 1999b; Ylikorkala et al,
1999; Boardman et al, 2000; Miyaki et al, 2000; Yoon et al, 2000;
Olschwang et al, 2001; Abed et al, 2001). Overall, most mutations
reported to date have been frameshift or nonsense mutations and
thus result in a truncated protein. In-frame deletions or missense
mutations appear to occur less frequently generally at conserved
amino acids in the kinase core.
Very few cases of PJS appear to be the consequence of large-
scale deletions of LKB1/STK11; however, not all studies have
systematically searched for such genetic changes (Table 2).
Disease expression in PJS is well documented to display inter-
and intrafamilial variation (Burdick et al, 1982; Foley et al, 1998).
Establishing a relationship between a number of the features of the
disease and genotype is, however, inherently problematic because
features typical of the disease are criteria for ascertainment.
Nevertheless, there was no evidence that the ages at diagnosis are
significantly different in carriers and noncarriers–mean ages of
index cases, 13.9 y and 13.6 years, respectively. Furthermore, the
distribution of polyps and rates of laparotomy were not
significantly different between the groups.
Some previously reported studies have reported no association
between detectable LKB1/STK11 mutation and family history
(Hemminki et al, 1998; Wang et al, 1999; Ylikorkala et al, 1999).
In our study, 13 of the 33 index cases had a family history of PJS
(39%). Of these 10 were carriers of mutations in LKB1/STK11
(77%), but only seven (35%) patients with sporadic disease had
mutations in LKB1/STK11. The higher prevalence of LKB1/STK11
mutations in PJS patients with a family history of the disease
compared with sporadic cases is statistically significant (P¼0.03).
Extra-gastrointestinal polyps are a recognised feature of PJS.
Four of the patients in our study had extra-intestinal polyps: one of
these harboured an LKB1/STK11 mutation and three did not.
Two patients had developed breast cancer since the diagnosis of
PJS had been made–at ages 52 and 35 years. Both are carriers of an
LKB1/STK11 mutation. In addition, one patient had presented at
age 6 with a Sertoli–Leydig cell stromal tumour. He did not
Table 1 Family history, clinical characteristics and LKB1/STK11 status of index patients
LKB1/STK11 mutation Clinical features Cancer
Patient Sex Age
Familial/
sporadic Exon Mutation
Effect of
mutation
Age at
diagnosis
Polyp
site in
GI tract
Intussusception
at age (years)
Extra-
intestinal
polyps
Index
case Relative
PJ77 M 23 F 1 208G4T E70X 13 SB 14 — — Mother cervix
Aunt colorectal
PJ48 M 37 S 1 180C4A Y60X 2 SB, LB 2, 7, 17, 24 — — —
PJ36 F 26 S 2 335–337del Q112fsX17 7 ST,SB,LB 8, 9,15,20 — — —
PJ60 F 61 S 2 368–370del Q123fsX6 16 SB, LB 16, 25, 55 — Breast Grandfather stomach
PJ52 F 34 F 3 454C4T Q152X 18 SB, LB 18 — — —
PJ56 F 40 F 3 426–428del V143fsX144 8 SB, LB 8, 18 Vocal cords — Mother stomach
PJ59 F 30 F 4 470ToC F157S 4 SB, LB 7, 14 ,27 — — —
PJ20 F 31 F 4 580G4A D194N 15 SB 15 — — Grandfather stomach
PJ69 F 31 S IVS5 IVS5+1G4A ?altered splicing 18 SB, LB 21, 24 — — —
PJ24 F 48 S 5 718–719insA S240fsX26 20 SB 20, 33 — — —
PJ45 F 31 F 5 725G4A G242E 10 ST, SB 4, 19, 26 — — Father pancreas
PJ47 F 31 F 6 815–816insA Y272X 25 ST, SB, LB 25, 29 — — —
PJ51 M 38 F 6 842–844del L282fsX5 4 ST, SB, LB 13, 14, 15,16,18,
22,23,33,35,36
—— —
PJ42 F 35 F 6 842–844del L282fsX5 10 SB, LB 30 — — Mother breast
PJ35 F 39 F 7 910C4T R304W 16 ST,SB 16 — Breast Mother, grandmother
breast
PJ33 M 61 S IVS8 IVS8-2A4G ?altered splicing 31 LB — — — —
PJ61 M 39 S IVS8 IVS8-2A4G ?altered splicing 19 ST, SB, LB 23, 32 — — —
PJ62 F 65 F ND — 13 SB, LB 13, 40 Nasal — —
PJ25 M 56 S ND — 20 SB, LB 20 — — —
PJ40 M 39 S ND — 26 SB, LB 28 — — —
PJ01 F 39 S ND — 5 SB 19 — — —
PJ39 M 21 S ND — 11 SB 11, 20 — — —
PJ49 F 54 F ND — 22 ST, SB, LB 22 , 52 — — —
PJ55 M 41 S ND — 15 ST, SB, LB 15, 20, 34 — — —
PJ66 F 22 S ND — 5 ST, SB, LB 9, 20 Ear and nasal — —
PJ67 M 35 F ND — 2 ST, SB, LB 2,12,13,14,18 — — Mother stomach
PJ70 F 37 S ND — 3 ST, SB, LB — — — Aunt breast
PJ37 F 40 S ND — 38 — — — —
PJ64 M 50 S ND — 5 ST, LB 7, 14, 26 Pharyngeal — —
PJ68 M 44 S ND — 23 ST, SB, LB 23 — — Mother oesophagus
PJ100 F 39 S ND 27 LB — — — —
PJ102 M 15 S ND 6 LB — — Sertoli cell —
PJ71 M 39 S ND — 34 SB — — — —
ST¼stomach; SB¼small bowel; LB¼large bowel. ND¼none detected. Positions refer to the LKB1 cDNA sequence (Genbank U63333).
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sTable 2 Location of LKB1/STK11 mutations in PJS patients in this study and published reports. Also shown are the cancers associated with mutations
Reference Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Exon 9
This study
a E70X
cx,co 112fs Q152X F157S 240fs IVS5+1 Y272X K296X IVS7-2
Y60X 123fs
b 143fs
st D194N G242E
p G4A 282fs
b E291V
se A4G
R304W
b
i
a E57X ex2_ex3 277fs 302del5 ex8 del
65fs del
E70X
L67P
Y60X
55fs
K84X
ii
a IVS3-1 156_307 240fs Y252X
G4A invdel 280fs
Iii Q220X
iv 38fs IVS1-1 139fs 244fs IVS5+2 Y246X
G4C insT B247del
280fsX6
280fsX4
v
a 52fs Q152X F157S 201fs IVS5+3 263fs
p 304fs
p, sb IVS7-1 W308X
K84X
b,cx, mm 137del4 N181Y Q220X A4T 257fs
co G4C
co
R86X 248fs
o, th
280fsX6
vi 175del2 262fs
G251S R304W
vii
a 50del4 D176N IVS5+5 IVS6 301fs W308C
191fs G4A del
viii
a 844insC
co, p, pr IVS6+3 R297S
co, ut 971del6
G4C H272Y
co, th
ix 54fs IVS1-2 Q100X D162N R297K 331fs
51fs A4G G163D
IVS1-1 L164M
G4C D194N
x
a L67R IVS1+ Y118X M136R IVS3-2 L182P IVS4-2 G242V IVS5+1 263fs 303del3 319fs
Y60X
b 1 117fs C132X
b, d A4G
p A4T 222fs G4A 251fs
57fs G4A 212fs 281fs
p, k
52del
k G242W 248fs
xi Y60X K108R 176fs 281fs K416X
ut
108del2
xii
a ex2-7del
d
xiii IVS1-2 S232P E256A P324L
A4C 342fs
xiv 41fs
se 172fs
p, o Q220X
157fs
b
xv 37fs ex2 del 188fs 213fs
221fs
262fs
xvi
a IVS1-2 Q170X
A4G
te
asearch for large-scale deletions made.
Mutation changes are described at the protein level.
Key to cancers: co¼colon; p¼pancreas; pr¼prostate; b¼breast; cx¼cervix; se¼sertoli cell; ut¼uterus; o¼ovary; k¼kidney; d¼duodenum; te¼testis.
References: i, Hemminki et al (1998); ii, Jenne et al (1998); iii, Gruber et al (1998); iv, Nakagawa et al (1998); v, Ylikorkala et al (1999); vi, Resta et al (1998); vii, Mehenni et al
(1998); viii, Boardman et al (2000); xi, Westerman et al (1999); x, Olschwang et al (2001); xi, Wang et al (1999); xii, Jiang et al (1999); xiii, Yoon et al (2000); xiv, Kruse et al
(1999); xv, Miyaki et al (2000); xvi, Abed et al (2001).
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sharbour an, LKB1/STK11 mutation. A high frequency of cancer was
seen in the relatives of the familial cases–stomach (n¼2, ages 32,
33 years), breast (n¼2, ages 39, 51 years), colorectal (n¼2, ages
43, 67 years), pancreas (n¼1; age 50 years) and adenoma
malignum of the cervix (n¼1, age 43 years). All but the one case
of stomach cancer was associated with LKB1/STK11 mutations.
Excluding the case presenting with a Sertoli–Leydig cell tumour,
the index cases and their relatives provided a total of 70
individuals with PJS from which cancer risks could be estimated.
These individuals provided a total of 2120 years at risk.
The probability of developing cancer by age 65 years in all PJS
patients was 37% (95% CI: 21–61%). The observation of seven
cancer deaths, four from gastrointestinal disease, between ages 5
and 65 years, equates to the SMR for all cancer of 9.9 (95% CI: 0.4–
20.4; Po0.001) and for gastrointestinal cancer of 24.8 (95% CI:
0.7–63.6; Po0.001). Confining the analysis to LKB1/STK11
mutation carriers, the probability of developing cancer by age 65
is 47% (95% CI: 27–73%), SMR of all and gastrointestinal cancers
of 13.2 (95% CI: 0.5–27.1, Po0.001) and 32.0 (95% CI: 0.5–81.8,
Po0.001), respectively. The risk of breast cancer in carriers was
markedly increased, 29% by age 65 (95% CI: 12–62%); SMR, 13.9
(95% CI: 0.2–50.3, Po0.001).
DISCUSSION
It is now well recognised that cancer risks are markedly elevated in
PJS (Giardello et al, 1987, 2000; Spigelman et al, 1989). Diagnosing
PJS in the absence of mutation data, especially in those without a
prior family history of the disease, can however be difficult as
pigmentation may not always be present or can fade and polyposis
is not always an invariable feature. Moreover, there is substantial
phenotypic overlap with other syndromes such as Carney complex
(Stratakis et al, 1998).
Over 75% of LKB1/STK11 mutations reported have been
frameshift or nonsense mutations and thus result in a truncated
protein (Hemminki et al, 1998; Jenne et al, 1998; Mehenni et al,
1998; Nakagawa et al, 1998; Resta et al, 1998; Jiang et al, 1999;
Kruse et al, 1999; Wang et al, 1999; Westerman et al, 1999b;
Ylikorkala et al, 1999; Boardman et al, 2000; Miyaki et al, 2000;
Yoon et al, 2000; Olschwang et al, 2001). In-frame deletions or
missense mutations appear to occur less commonly at conserved
amino acids within the kinase core of the expressed protein.
Mutations reported to date have been scattered across exons 1–8.
The distribution of mutations within the protein kinase core
encoding region of LKB1/STK11 does not appear to be random
(Po0.05) and exons 1 and 6 appear to be preferentially involved
accounting for B38% of all reported mutations. Only one
mutation has been described in exon 9 (Wang et al, 1999)–a
nonsense mutation removing 56 residues from the protein of 434
amino acids and as such resides outside the protein kinase core.
Although the case was familial, other members of the family were
not evaluated and hence the pathological significance of this
mutation is questionable.
Our study showed that the risk for cancer, gastrointestinal and
breast, associated with germline LKB1/STK11 mutations is high
and supports recent implementation of screening protocols
suggested for patients (Wirtzfeld et al, 2001). In contrast to a
number of other inherited cancer syndromes, cancer risks
associated with germline LKB1/STK11 mutations cancer risks are
not so site specific. LKB1/STK11 functions as a tumour suppressor
in hamartomous polyps and in neoplasms. Some neoplasms
develop from hamartomas; however, as LKB1/STK11 has a role in a
number of pathways involved in control of cell growth, it is likely
that some mutations may confer an increased cancer risk through
alternative mechanisms.
In our study, cancers were found in association with mutations
in most exons. From studies published so far, there does not seem
to be a specifically higher prevalence of any cancer associated with
mutations in specific exons (Figure 1). However, one of the
mutations we detected, R304W, appeared to be associated with a
high risk of breast cancer. It is highly conceivable that certain
mutations may be associated with higher risks of cancer at certain
sites, as seen with BRCA2 (The Breast Cancer Linkage Consortium
1999; Murphy et al, 2002). To formally assess such relationships
will require a large number of observations.
Since Hemminki et al (1998) first showed that germline
mutations in LKB1/STK11 cause PJS, a number of studies have
examined the prevalence of mutations in the syndrome. In our
study, we identified the LKB1/STK11 mutation in 52% of our
patients, implying that approximately half of the cases are not
caused by mutations in this gene, reinforcing the suggestion that
the disease is genetically heterogeneous. Other studies have
reported similar estimates for the prevalence of germline LKB1/
STK11 mutations in PJS patients (Wang et al, 1999; Westerman
et al, 1999b; Yoon et al, 2000; Olschwang et al, 2001). Some
mutations may have gone undetected such as those in regulatory
elements which may be undetectable in some PCR-based assays;
however, families with PJS unlinked to 19p13.3 have been reported
confirming that the disease is heterogeneous (Mehenni et al, 1998;
Jiang et al, 1999; Westerman et al, 1999b; Yoon et al, 2000).
Studies that have formally estimated cancer risks in PJS have not
computed separate estimates according to LKB1/STK11 status.
Olschwang et al (2001) recently reported a high frequency of
proximal bile duct adenocarcinomas in PJS who did not carry
LKB1/STK11 mutations. Similarly, Boardman et al (2000) reported
a high frequency of cancer in this group of patients, although no
cases of bile duct cancers were observed. In our study, we had few
familial cases not caused by LKB1/STK11 mutations to enable us to
compute a separate estimate of risk for noncarriers.
In conclusion, our results confirm that there is significant
genetic heterogeneity in PJS. Future studies characterising the
mutational status and disease manifestation in large numbers of
PJS patients will allow better genotype–phenotype correlation to
be made, which should assist clinicians in formulating cancer
surveillance and individual predictive genetic testing.
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